



US009060723B2

(12) **United States Patent**
Escutia et al.

(10) **Patent No.:** **US 9,060,723 B2**
(45) **Date of Patent:** ***Jun. 23, 2015**

(54) **BODY FLUID SAMPLING ARRANGEMENTS**

(71) Applicant: **Intuity Medical, Inc.**, Sunnyvale, CA (US)

(72) Inventors: **Raul Escutia**, Sunnyvale, CA (US);
Jeffrey L. Emery, Redwood City, CA (US); **Craig M. Litherland**, Cupertino, CA (US)

(73) Assignee: **Intuity Medical, Inc.**, Sunnyvale, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/446,262**

(22) Filed: **Jul. 29, 2014**

(65) **Prior Publication Data**

US 2014/0336480 A1 Nov. 13, 2014

Related U.S. Application Data

(60) Continuation of application No. 13/752,261, filed on Jan. 28, 2013, now Pat. No. 8,795,201, which is a continuation of application No. 13/197,592, filed on Aug. 3, 2011, now Pat. No. 8,360,993, which is a

(Continued)

(51) **Int. Cl.**
A61B 5/151 (2006.01)
A61B 5/15 (2006.01)

(Continued)

(52) **U.S. Cl.**
CPC **A61B 5/150099** (2013.01); **A61B 5/1411** (2013.01); **A61B 5/1427** (2013.01);

(Continued)

(58) **Field of Classification Search**

USPC 600/573, 576–579, 583, 584;
606/181–183

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

842,690 A 1/1907 Oswalt
D137,874 S 5/1944 Partridge

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2 513 465 A1 8/2004
DE 199 22 413 A1 11/2000

(Continued)

OTHER PUBLICATIONS

Advisory Action mailed on Feb. 2, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 3 pages.

(Continued)

Primary Examiner — Max Hindenburg


Assistant Examiner — John Pani

(74) *Attorney, Agent, or Firm* — Morrison & Foerster LLP

(57) **ABSTRACT**

An arrangement for producing a sample of body fluid from an opening created in a skin surface at a sampling site including a cartridge with a plurality of compartments and a plurality of sampling sites, and a detector assembly. Each sampling site includes a skin-penetration member having a first end configured to pierce the surface of the skin and an inner lumen in communication with the first end, a spring actuator operatively associated with the skin-penetration member, and a needle hub connecting the skin-penetration member and the spring actuator. The needle hub includes a reagent pad and the spring actuator is configured to drive the skin-penetration member to form the wound opening. Each compartment at least partially encloses the skin-penetration member, the spring actuator, and the needle hub of a respective sampling site.

11 Claims, 9 Drawing Sheets



Related U.S. Application Data

continuation of application No. 11/941,403, filed on Nov. 16, 2007, now Pat. No. 8,012,104, which is a division of application No. 11/529,613, filed on Sep. 29, 2006, now Pat. No. 8,012,103.

- (60) Provisional application No. 60/721,966, filed on Sep. 30, 2005.

(51) **Int. Cl.**

A61B 5/155 (2006.01)

A61B 5/145 (2006.01)

A61B 5/1486 (2006.01)

A61B 5/00 (2006.01)

G01N 21/03 (2006.01)

A61B 5/157 (2006.01)

A61B 5/1468 (2006.01)

(52) **U.S. Cl.**

CPC *A61B5/14532* (2013.01); *A61B 5/14546* (2013.01); *A61B 5/1486* (2013.01); *A61B 5/150389* (2013.01); *A61B 5/151* (2013.01); *A61B 5/15146* (2013.01); *A61B 5/15186* (2013.01); *A61B 5/681* (2013.01); *A61B 5/6824* (2013.01); *A61B 5/6828* (2013.01); *A61B 2560/0443* (2013.01); *A61B 2560/0462* (2013.01); *G01N 21/0303* (2013.01); *A61B 5/15121* (2013.01); *A61B 5/150022* (2013.01); *A61B 5/150068* (2013.01); *A61B 5/150076* (2013.01); *A61B 5/150083* (2013.01); *A61B 5/150167* (2013.01); *A61B 5/150229* (2013.01); *A61B 5/150412* (2013.01); *A61B 5/150946* (2013.01); *A61B 5/150954* (2013.01); *A61B 5/150969* (2013.01); *A61B 5/150984* (2013.01); *A61B 5/15111* (2013.01); *A61B 5/15113* (2013.01); *A61B 5/15117* (2013.01); *A61B 5/15123* (2013.01); *A61B 5/15151* (2013.01); *A61B 5/15161* (2013.01); *A61B 5/15163* (2013.01); *A61B 5/155* (2013.01); *A61B 5/157* (2013.01); *A61B 5/15148* (2013.01); *A61B 5/1468* (2013.01); *A61B 5/150396* (2013.01); *A61B 5/150343* (2013.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,749,797 A 3/1950 Harks
3,092,465 A 6/1963 Adams, Jr.
3,310,002 A 3/1967 Wilburn
3,620,209 A 11/1971 Kravitz
3,623,475 A 11/1971 Sanz et al.
3,626,929 A 12/1971 Sanz et al.
3,630,957 A 12/1971 Rey
D223,165 S 3/1972 Komendat
3,723,064 A 3/1973 Liotta
3,741,197 A 6/1973 Sanz et al.
3,961,898 A 6/1976 Neeley et al.
4,014,328 A 3/1977 Cluff et al.
4,042,335 A 8/1977 Clement
4,057,394 A 11/1977 Genshaw
4,109,655 A 8/1978 Chacornac
4,254,083 A 3/1981 Columbus
4,258,001 A 3/1981 Pierce et al.
4,260,257 A 4/1981 Neeley et al.
4,289,459 A 9/1981 Neeley et al.
4,321,397 A 3/1982 Nix et al.
4,350,762 A 9/1982 DeLuca et al.
4,394,512 A 7/1983 Batz
4,414,975 A 11/1983 Ryder et al.
4,416,279 A 11/1983 Lindner et al.

4,418,037 A 11/1983 Katsuyama et al.
4,422,941 A 12/1983 Vaughan, Jr. et al.
4,429,700 A 2/1984 Thees et al.
4,627,445 A 12/1986 Garcia et al.
4,637,403 A 1/1987 Garcia et al.
4,637,406 A 1/1987 Guinn et al.
4,653,513 A 3/1987 Dombrowski
4,661,319 A 4/1987 Lape
4,702,261 A 10/1987 Cornell et al.
4,711,250 A 12/1987 Gilbaugh, Jr. et al.
4,737,458 A 4/1988 Batz et al.
4,767,415 A 8/1988 Duffy
4,774,192 A 9/1988 Terminiello et al.
4,790,979 A 12/1988 Terminiello et al.
4,794,926 A 1/1989 Munsch et al.
4,815,843 A 3/1989 Tiefenthaler et al.
4,829,470 A 5/1989 Wang
4,846,785 A 7/1989 Cassou et al.
4,887,306 A 12/1989 Hwang et al.
4,920,977 A 5/1990 Haynes
4,930,525 A 6/1990 Palestrant
4,935,346 A 6/1990 Phillips
4,953,552 A 9/1990 De Marzo
4,966,646 A 10/1990 Zdeblick
4,995,402 A 2/1991 Smith
5,029,583 A 7/1991 Meserol
5,049,487 A 9/1991 Phillips et al.
5,050,617 A 9/1991 Columbus et al.
5,059,394 A 10/1991 Phillips et al.
5,077,199 A 12/1991 Basagni et al.
5,094,943 A 3/1992 Siedel et al.
5,116,759 A 5/1992 Klainer et al.
5,131,404 A 7/1992 Neeley et al.
5,141,868 A 8/1992 Shanks et al.
5,145,565 A 9/1992 Kater et al.
5,146,437 A 9/1992 Boucheron
5,153,416 A 10/1992 Neeley
5,164,575 A 11/1992 Neeley et al.
5,166,498 A 11/1992 Neeley
5,174,291 A 12/1992 Schoonen et al.
5,176,632 A 1/1993 Bernardi
5,179,005 A 1/1993 Phillips et al.
5,183,741 A 2/1993 Arai et al.
5,196,302 A 3/1993 Kidwell
5,208,163 A 5/1993 Charlton et al.
5,213,966 A 5/1993 Vuorinen et al.
5,217,480 A 6/1993 Haber et al.
5,218,966 A 6/1993 Yamasawa
5,223,219 A 6/1993 Subramanian et al.
5,234,818 A 8/1993 Zimmermann et al.
5,241,969 A 9/1993 Carson et al.
5,251,126 A 10/1993 Kahn et al.
D341,848 S 11/1993 Bigelow et al.
5,275,159 A 1/1994 Griebel
5,278,079 A 1/1994 Gubinski et al.
5,288,646 A 2/1994 Lundsgaard et al.
5,299,571 A 4/1994 Mastrototaro
5,301,686 A 4/1994 Newman
5,302,513 A 4/1994 Mike et al.
5,304,468 A 4/1994 Phillips et al.
5,306,623 A 4/1994 Kiser et al.
5,308,767 A 5/1994 Terashima
5,320,607 A 6/1994 Ishibashi
5,354,537 A 10/1994 Moreno
5,360,595 A 11/1994 Bell et al.
5,368,047 A 11/1994 Suzuki et al.
5,383,512 A 1/1995 Jarvis
5,390,671 A 2/1995 Lord et al.
5,399,316 A 3/1995 Yamada
5,401,110 A 3/1995 Neeley
5,402,798 A 4/1995 Swierczek et al.
5,441,513 A 8/1995 Roth
5,451,350 A 9/1995 Macho et al.
5,458,140 A 10/1995 Eppstein et al.
5,460,777 A 10/1995 Kitajima et al.
5,460,968 A 10/1995 Yoshida et al.
5,482,473 A 1/1996 Lord et al.
5,506,200 A 4/1996 Hirschhoff et al.
5,507,288 A 4/1996 Böcker et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

5,508,200	A	4/1996	Tiffany et al.	5,986,754	A	11/1999	Harding
5,510,266	A	4/1996	Bonner et al.	5,989,409	A	11/1999	Kurnik et al.
5,514,152	A	5/1996	Smith	5,993,189	A	11/1999	Mueller et al.
5,568,806	A	10/1996	Cheney, II et al.	6,001,067	A	12/1999	Shults et al.
5,569,287	A	10/1996	Tezuka et al.	6,005,545	A	12/1999	Nishida et al.
5,575,403	A	11/1996	Charlton et al.	6,010,463	A	1/2000	Lauks et al.
5,577,499	A	11/1996	Teves	6,010,519	A *	1/2000	Mawhirt et al. 606/181
5,582,184	A	12/1996	Erickson et al.	6,014,135	A	1/2000	Fernandes
5,586,553	A	12/1996	Halili et al.	6,014,577	A	1/2000	Henning et al.
5,591,139	A	1/1997	Lin et al.	6,023,629	A	2/2000	Tamada
5,611,809	A	3/1997	Marshall et al.	6,027,459	A	2/2000	Shain et al.
5,624,458	A	4/1997	Lipscher	6,030,827	A	2/2000	Davis et al.
5,630,986	A	5/1997	Charlton et al.	6,032,059	A	2/2000	Henning et al.
5,632,410	A	5/1997	Moulton et al.	6,036,924	A	3/2000	Simons et al.
5,636,632	A	6/1997	Bommannan et al.	6,041,253	A	3/2000	Kost et al.
5,647,851	A	7/1997	Pokras	6,050,988	A	4/2000	Zuck
5,658,515	A	8/1997	Lee et al.	6,056,701	A	5/2000	Duchon et al.
5,660,791	A	8/1997	Brenneman et al.	6,056,734	A	5/2000	Jacobsen et al.
5,676,850	A	10/1997	Reed et al.	6,058,321	A	5/2000	Swayze et al.
5,680,858	A	10/1997	Hansen et al.	6,059,815	A	5/2000	Lee et al.
5,681,484	A	10/1997	Zanzucchi et al.	6,061,128	A	5/2000	Zweig et al.
5,682,233	A	10/1997	Brinda	6,063,039	A	5/2000	Cunningham et al.
5,697,901	A	12/1997	Eriksson	6,071,251	A	6/2000	Cunningham et al.
5,701,181	A	12/1997	Boiarski et al.	6,071,294	A	6/2000	Simons et al.
5,701,910	A	12/1997	Powles et al.	6,077,660	A	6/2000	Wong et al.
5,705,018	A	1/1998	Hartley	6,080,116	A	6/2000	Erickson et al.
5,708,787	A	1/1998	Nakano et al.	6,083,196	A	7/2000	Trautman et al.
5,715,417	A	2/1998	Gardien et al.	6,086,544	A	7/2000	Hibner et al.
5,730,753	A	3/1998	Morita	6,090,790	A	7/2000	Eriksson
5,735,273	A	4/1998	Kurnik et al.	6,091,975	A	7/2000	Daddona et al.
5,736,103	A	4/1998	Pugh	6,093,156	A	7/2000	Cunningham et al.
5,741,211	A	4/1998	Renirie et al.	6,097,831	A	8/2000	Wieck et al.
5,746,217	A	5/1998	Erickson et al.	6,099,484	A	8/2000	Douglas et al.
5,746,720	A	5/1998	Stouder, Jr.	6,100,107	A	8/2000	Lei et al.
5,757,666	A	5/1998	Schreiber et al.	6,102,933	A	8/2000	Lee et al.
5,759,364	A	6/1998	Charlton et al.	6,103,033	A	8/2000	Say et al.
5,766,066	A	6/1998	Ranniger	6,103,197	A	8/2000	Werner
5,771,890	A	6/1998	Tamada	6,106,751	A	8/2000	Talbot et al.
5,797,693	A	8/1998	Jaeger	6,118,126	A	9/2000	Zanzucchi
5,801,057	A	9/1998	Smart et al.	6,120,676	A	9/2000	Heller et al.
5,807,375	A	9/1998	Gross et al.	6,123,861	A	9/2000	Santini, Jr. et al.
5,820,570	A	10/1998	Erickson et al.	6,126,899	A	10/2000	Woudenberg et al.
5,827,183	A	10/1998	Kurnik et al.	6,132,449	A	10/2000	Lum et al.
5,840,020	A	11/1998	Heinonen et al.	6,139,562	A	10/2000	Mauze et al.
5,841,126	A	11/1998	Fossum et al.	6,142,939	A	11/2000	Eppstein et al.
5,843,692	A	12/1998	Phillips et al.	6,152,942	A	11/2000	Brenneman et al.
5,846,837	A	12/1998	Thym et al.	6,162,639	A	12/2000	Douglas
5,854,074	A	12/1998	Charlton et al.	6,175,752	B1	1/2001	Say et al.
D403,975	S	1/1999	Douglas et al.	6,176,865	B1	1/2001	Mauze et al.
5,855,801	A	1/1999	Lin et al.	6,183,434	B1	2/2001	Eppstein et al.
5,856,195	A	1/1999	Charlton et al.	6,183,489	B1	2/2001	Douglas et al.
5,858,194	A	1/1999	Bell	6,187,210	B1	2/2001	Lebouiz et al.
5,866,281	A	2/1999	Guckel et al.	6,192,891	B1	2/2001	Gravel et al.
5,871,494	A	2/1999	Simons et al.	6,200,296	B1	3/2001	Dibiasi et al.
5,879,310	A	3/1999	Sopp et al.	6,206,841	B1	3/2001	Cunningham et al.
5,879,326	A	3/1999	Godshall et al.	6,214,626	B1	4/2001	Meller et al.
5,879,367	A	3/1999	Latterell et al.	6,219,574	B1	4/2001	Cormier et al.
5,891,053	A	4/1999	Sesekura	6,228,100	B1	5/2001	Schraga
5,893,870	A	4/1999	Talen et al.	6,230,051	B1	5/2001	Cormier et al.
5,911,711	A	6/1999	Pelkey	6,231,531	B1	5/2001	Lum et al.
5,911,737	A	6/1999	Lee et al.	6,241,862	B1	6/2001	McAleer et al.
5,912,139	A	6/1999	Iwata et al.	6,242,207	B1	6/2001	Douglas et al.
5,925,021	A	7/1999	Castellano et al.	6,245,215	B1	6/2001	Douglas et al.
5,928,207	A	7/1999	Pisano et al.	6,251,083	B1	6/2001	Yum et al.
5,930,873	A	8/1999	Wyser	6,251,260	B1	6/2001	Heller et al.
5,938,679	A	8/1999	Freeman et al.	6,254,586	B1	7/2001	Mann et al.
5,945,678	A	8/1999	Yanagisawa	6,255,061	B1	7/2001	Mori et al.
5,951,492	A	9/1999	Douglas et al.	6,256,533	B1	7/2001	Yuzhakov et al.
5,951,493	A	9/1999	Douglas et al.	6,268,162	B1	7/2001	Phillips et al.
5,954,685	A	9/1999	Tierney	6,271,045	B1	8/2001	Douglas et al.
5,962,215	A	10/1999	Douglas et al.	6,272,364	B1	8/2001	Kurnik
5,968,760	A	10/1999	Phillips et al.	6,283,926	B1	9/2001	Cunningham et al.
5,968,765	A	10/1999	Grage et al.	6,289,230	B1	9/2001	Chaiken et al.
5,971,941	A	10/1999	Simons et al.	6,298,254	B2	10/2001	Tamada
5,972,294	A	10/1999	Smith et al.	6,299,578	B1	10/2001	Kurnik et al.
				6,309,351	B1	10/2001	Kurnik et al.
				D450,711	S	11/2001	Istvan et al.
				6,312,612	B1	11/2001	Sherman et al.
				6,312,888	B1	11/2001	Wong et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,322,808	B1	11/2001	Trautman et al.	7,887,494	B2	2/2011	Emery et al.
6,329,161	B1	12/2001	Heller et al.	D642,191	S	7/2011	Barnett et al.
6,331,266	B1	12/2001	Powell et al.	8,012,103	B2	9/2011	Escutia et al.
6,332,871	B1	12/2001	Douglas et al.	8,012,104	B2	9/2011	Escutia et al.
6,334,856	B1	1/2002	Allen et al.	8,360,993	B2	1/2013	Escutia et al.
6,350,273	B1	2/2002	Minagawa et al.	8,360,994	B2	1/2013	Escutia et al.
6,352,514	B1	3/2002	Douglas et al.	8,795,201	B2 *	8/2014	Escutia et al. 600/583
6,356,776	B1	3/2002	Berner et al.	2001/0001034	A1	5/2001	Douglas
6,358,265	B1	3/2002	Thorne, Jr. et al.	2001/0027328	A1	10/2001	Lum et al.
6,364,890	B1	4/2002	Lum et al.	2001/0053891	A1	12/2001	Ackley
6,375,626	B1	4/2002	Allen et al.	2002/0002326	A1	1/2002	Causey, III et al.
6,375,627	B1	4/2002	Mauze et al.	2002/0002344	A1	1/2002	Douglas et al.
6,379,969	B1	4/2002	Mauze et al.	2002/0004640	A1	1/2002	Conn et al.
6,391,005	B1	5/2002	Lum et al.	2002/0006355	A1	1/2002	Whitson
6,409,679	B2	6/2002	Pyo	2002/0016568	A1	2/2002	Lebel et al.
6,428,664	B1	8/2002	BhulLar et al.	2002/0020688	A1	2/2002	Sherman et al.
6,449,608	B1	9/2002	Morita et al.	2002/0023852	A1	2/2002	Mcivor et al.
6,455,324	B1	9/2002	Douglas	2002/0042594	A1	4/2002	Lum et al.
6,500,134	B1	12/2002	Cassone	2002/0052618	A1	5/2002	Haar et al.
6,520,973	B1	2/2003	McGarry	2002/0087056	A1	7/2002	Aceti et al.
6,530,892	B1	3/2003	Kelly	2002/0136667	A1	9/2002	Subramanian et al.
6,537,243	B1	3/2003	Henning et al.	2002/0137998	A1	9/2002	Smart et al.
6,540,675	B2	4/2003	Aceti et al.	2002/0160520	A1	10/2002	Orloff et al.
6,544,475	B1	4/2003	Douglas et al.	2002/0168290	A1	11/2002	Yuzhakov et al.
6,555,061	B1	4/2003	Leong et al.	2002/0169394	A1	11/2002	Eppstein et al.
6,558,624	B1	5/2003	Lemmon et al.	2002/0169411	A1	11/2002	Sherman et al.
6,579,690	B1	6/2003	Bonnecaze et al.	2002/0177761	A1	11/2002	Orloff et al.
6,602,205	B1	8/2003	Erickson et al.	2002/0183102	A1	12/2002	Withers et al.
6,612,111	B1	9/2003	Hodges et al.	2002/0188223	A1	12/2002	Perez et al.
6,616,616	B2	9/2003	Fritz et al.	2002/0198444	A1	12/2002	Uchigaki et al.
6,626,874	B1	9/2003	Duchamp	2003/0012693	A1	1/2003	Otillar et al.
6,656,167	B2	12/2003	Numao et al.	2003/0028087	A1	2/2003	Yuzhakov et al.
6,679,852	B1	1/2004	Schmelzeisen-Redeker et al.	2003/0028125	A1	2/2003	Yuzhakov et al.
6,706,000	B2	3/2004	Perez et al.	2003/0039587	A1	2/2003	Niermann
6,706,049	B2	3/2004	Moerman	2003/0060730	A1	3/2003	Perez
6,706,159	B2	3/2004	Moerman et al.	2003/0083685	A1	5/2003	Freeman et al.
6,740,800	B1	5/2004	Cunningham	2003/0083686	A1	5/2003	Freeman et al.
6,748,275	B2	6/2004	Lattner et al.	2003/0116596	A1	6/2003	Terasawa
6,753,187	B2	6/2004	Cizdziel et al.	2003/0135166	A1	7/2003	Gonnelli
6,766,817	B2	7/2004	da Silva	2003/0135333	A1	7/2003	Aceti
6,793,633	B2	9/2004	Douglas et al.	2003/0153844	A1	8/2003	Smith et al.
6,830,669	B2	12/2004	Miyazaki et al.	2003/0153900	A1 *	8/2003	Aceti et al. 604/890.1
6,836,678	B2	12/2004	Tu	2003/0175987	A1	9/2003	Verdonk et al.
6,837,858	B2	1/2005	Cunningham et al.	2003/0206302	A1	11/2003	Pugh
6,847,451	B2	1/2005	Pugh	2003/0207441	A1	11/2003	Eyster et al.
6,918,404	B2	7/2005	Da Silva	2003/0208113	A1	11/2003	Mault et al.
6,919,960	B2	7/2005	Hansen et al.	2003/0211619	A1	11/2003	Olson et al.
6,923,764	B2	8/2005	Aceti et al.	2003/0212344	A1	11/2003	Yuzhakov et al.
6,936,476	B1	8/2005	Anderson et al.	2003/0212347	A1 *	11/2003	Sohrab 600/584
6,988,996	B2	1/2006	Roe et al.	2004/0010207	A1	1/2004	Flaherty et al.
7,004,928	B2	2/2006	Aceti et al.	2004/0030353	A1	2/2004	Schmelzeisen-redeker et al.
7,011,630	B2	3/2006	Desai et al.	2004/0049219	A1	3/2004	Briggs et al.
7,025,774	B2	4/2006	Freeman et al.	2004/0059256	A1	3/2004	Perez
7,052,652	B2	5/2006	Zanzucchi et al.	2004/0073140	A1	4/2004	Douglas et al.
7,066,586	B2	6/2006	Da Silva	2004/0092842	A1	5/2004	Boecker et al.
7,066,890	B1	6/2006	Lam et al.	2004/0092995	A1	5/2004	Boecker et al.
7,141,058	B2	11/2006	Briggs et al.	2004/0094432	A1	5/2004	Neel et al.
7,156,809	B2	1/2007	Quy	2004/0096959	A1	5/2004	Stiene et al.
7,192,061	B2	3/2007	Martin	2004/0098009	A1	5/2004	Boecker et al.
D540,343	S	4/2007	Cummins	2004/0102803	A1	5/2004	Boecker et al.
7,223,365	B2	5/2007	Von Der Goltz	2004/0122339	A1	6/2004	Roe et al.
7,225,008	B1	5/2007	Ward et al.	2004/0132167	A1	7/2004	Rule et al.
7,226,461	B2	6/2007	Boecker et al.	2004/0138588	A1	7/2004	Saikley et al.
7,258,673	B2	8/2007	Racchini et al.	2004/0155084	A1	8/2004	Brown
D551,243	S	9/2007	Young	2004/0157339	A1	8/2004	Burke et al.
7,270,970	B2	9/2007	Anderson et al.	2004/0178218	A1	9/2004	Schomakers et al.
7,297,151	B2	11/2007	Boecker et al.	2004/0186394	A1	9/2004	Roe et al.
7,343,188	B2	3/2008	Sohrab	2004/0191119	A1	9/2004	Zanzucchi et al.
7,344,507	B2	3/2008	Briggs et al.	2004/0202576	A1	10/2004	Aceti et al.
7,379,167	B2	5/2008	Mawhirt et al.	2004/0236251	A1	11/2004	Roe et al.
7,427,377	B2	9/2008	Zanzucchi et al.	2004/0238675	A1	12/2004	Banaszkiewicz et al.
D599,373	S	9/2009	Kobayashi et al.	2004/0249253	A1 *	12/2004	Racchini et al. 600/347
D601,578	S	10/2009	Poulet et al.	2004/0259180	A1	12/2004	Burke et al.
7,682,318	B2	3/2010	Alden et al.	2005/0010134	A1	1/2005	Douglas et al.
7,803,123	B2	9/2010	Perez et al.	2005/0015020	A1	1/2005	LeVaughn et al.
				2005/0096686	A1	5/2005	Allen
				2005/0106713	A1	5/2005	Phan et al.
				2005/0159678	A1	7/2005	Taniike et al.
				2005/0187532	A1	8/2005	Thurau et al.

References Cited

JP	2003-180417	A2	7/2003
JP	2004-000598	A	1/2004
JP	2004-500948	A	1/2004
JP	2004-117339	A	4/2004
JP	2004-522500	A	7/2004
JP	2004-528936	A	9/2004
JP	2005-503538	A	2/2005
JP	2005-087613	A	4/2005
JP	2006-512969	A	4/2005
JP	3638958	B2	4/2005
JP	2005-525149	A	8/2005
JP	2005-237938	A	9/2005
JP	2005-525846	A	9/2005
JP	2005-527254	A	9/2005
JP	2006-506185	A	2/2006
JP	2006-512974	A	4/2006
JP	2006-516723	A	7/2006
JP	2006-521555	A	9/2006
JP	2006-527013	A	11/2006
JP	2007-014381	A	1/2007
JP	2007-136198	A	6/2007
JP	2007-521031	A	8/2007
JP	2007-537804	A	12/2007
WO	WO-91/14212	A1	9/1991
WO	WO-94/13203	A1	6/1994
WO	WO-95/10223	A2	4/1995
WO	WO-95/10223	A3	4/1995
WO	WO-96/04857	A1	2/1996
WO	WO-96/14026	A1	5/1996
WO	WO-96/25088	A1	8/1996
WO	WO-97/04707	A1	2/1997
WO	WO-97/15227	A1	5/1997
WO	WO-97/29847	A1	8/1997
WO	WO-97/30344	A1	8/1997
WO	WO-97/41421	A1	11/1997
WO	WO-98/31275	A1	7/1998
WO	WO-98/35225	A1	8/1998
WO	WO-99/12008	A1	3/1999
WO	WO-99/44508	A1	9/1999
WO	WO-99/58051	A1	11/1999
WO	WO-00/09184	A1	2/2000
WO	WO-00/13573	A1	3/2000
WO	WO-00/14269	A1	3/2000
WO	WO-00/14535	A1	3/2000
WO	WO-00/18449	A2	4/2000
WO	WO-00/18449	A3	4/2000
WO	WO-00/36400	A1	6/2000
WO	WO-00/42422	A1	7/2000
WO	WO-00/74763	A2	12/2000
WO	WO-00/74763	A3	12/2000
WO	WO-00/78208	A1	12/2000
WO	WO-01/16575	A1	3/2001
WO	WO-01/52727	A1	7/2001
WO	WO-01/64105	A1	9/2001
WO	WO-01/64105	C2	9/2001
WO	WO-01/72220	A1	10/2001
WO	WO-01/80728	A1	11/2001
WO	WO-01/85233	A2	11/2001
WO	WO-01/85233	A3	11/2001
WO	WO-01/91634	A2	12/2001
WO	WO-01/91634	A3	12/2001
WO	WO-02/00101	A1	1/2002
WO	WO-02/00101	A3	1/2002
WO	WO-02/49507	A1	6/2002
WO	WO-02/49509	A2	6/2002
WO	WO-02/49509	A3	6/2002
WO	WO-02/082052	A2	10/2002
WO	WO-02/082052	A3	10/2002
WO	WO-02/093144	A1	11/2002
WO	WO-02/100251	A2	12/2002
WO	WO-02/100251	A3	12/2002
WO	WO-02/101359	A2	12/2002
WO	WO-02/101359	A3	12/2002
WO	WO-03/030984	A1	4/2003
WO	WO-03/066128	A2	8/2003
WO	WO-03/066128	A3	8/2003
WO	WO-03/070099	A1	8/2003
WO	WO-03/071940	A1	9/2003
WO	WO-03/071940	C1	9/2003

FOREIGN PATENT DOCUMENTS

DE	103 02-501 A1	8/2004
EP	0 396-016 A2	11/1990
EP	0 396-016 A3	11/1990
EP	0 255-338 A2	2/1998
EP	1 266-607 A2	12/2002
EP	1 266-607 A3	12/2002
EP	1 360-934 A1	11/2003
EP	1 360-934 B1	11/2003
EP	1 486-766 A1	12/2004
EP	1 486-766 B1	12/2004
EP	1 529-489 A1	5/2005
EP	1 529-489 B1	5/2005
EP	1 769-735 A1	4/2007
JP	63-305841 A	12/1988
JP	3-63570 A	3/1991
JP	03093189 A	4/1991
JP	7-67861 A	3/1995
JP	7-213925 A	8/1995
JP	9-168530 A	6/1997
JP	9-313465 A	9/1997
JP	9-266889 A	10/1997
JP	9-294737 A	11/1997
JP	10-024028 A	1/1998
JP	10-318970 A	12/1998
JP	2000126161 A	5/2000
JP	2000-168754 A	6/2000
JP	2000-254111 A	9/2000
JP	2001-159618 A	6/2001
JP	2001-305096 A	10/2001
JP	2001-330581 A	11/2001
JP	2002-502045 A	1/2002
JP	2002-514453 A	5/2002

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	WO-2004/045375	A2	6/2004
WO	WO-2004/045375	A3	6/2004
WO	WO-2004/062499	A1	7/2004
WO	WO-2004/062500	A1	7/2004
WO	WO-2004/062500	C1	7/2004
WO	WO-2004/064636	A1	8/2004
WO	WO-2005/006939	A2	1/2005
WO	WO-2005/006939	A3	1/2005
WO	WO-2005/009238	A1	2/2005
WO	WO-2005/013824	A1	2/2005
WO	WO-2005/018709	A2	3/2005
WO	WO-2005/018709	A3	3/2005
WO	WO-2005/084546	A2	9/2005
WO	WO-2005/084546	A3	9/2005
WO	WO-2005/085995	A1	9/2005
WO	WO-2005/112763	A1	12/2005
WO	WO-2007/041063	A2	4/2007
WO	WO-2007/041063	A3	4/2007
WO	WO-2007/041244	A2	4/2007
WO	WO-2007/041244	A3	4/2007
WO	WO-2007/041287	A2	4/2007
WO	WO-2007/041287	A3	4/2007
WO	WO-2007/041355	A2	4/2007
WO	WO-2007/041355	A3	4/2007

OTHER PUBLICATIONS

- Advisory Action mailed on Apr. 8, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 3 pages.
- Extended European Search Report mailed on Jan. 22, 2013, for EP Application No. 12182900.6, filed on Sep. 29, 2006, 6 pages.
- Final Office Action mailed on Jul. 9, 2008, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 19 pages.
- Final Office Action mailed on Nov. 23, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 20 pages.
- Final Office Action mailed on Jan. 21, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 7 pages.
- International Search Report mailed on Aug. 16, 2007 for PCT Application No. PCT/US2006/038163, filed on Sep. 29, 2006, 1 page.
- Interview Summary mailed on Jan. 13, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 4 pages.
- Interview Summary mailed on Nov. 1, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 3 pages.
- Interview Summary mailed on May 17, 2012, for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 3 pages.
- Interview Summary mailed on May 17, 2012, for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 3 pages.
- Interview Summary mailed on Aug. 27, 2012, for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 3 pages.
- Interview Summary mailed on Aug. 27, 2012, for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 3 pages.
- Non-Final Office Action mailed on Dec. 12, 2007, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 13 pages.
- Non-Final Office Action mailed on Apr. 28, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 21 pages.
- Non-Final Office Action mailed on Jun. 4, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 23 pages.
- Non-Final Office Action mailed on Mar. 23, 2012, for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 7 pages.
- Non-Final Office Action mailed on Mar. 23, 2012, for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 6 pages.
- Notice of Allowance mailed on May 3, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 12 pages.
- Request for Continued Examination filed on Feb. 4, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 2 pages.
- Request for Continued Examination filed on Apr. 23, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 2 pages.
- Response to Non-Final Office Action filed on Apr. 11, 2008, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 18 pages.
- Response to Non-Final Office Action filed on Jul. 28, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 27 pages.
- Response to Non-Final Office Action filed on Nov. 4, 2010 for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 18 pages.
- Response to Non-Final Office Action filed on Aug. 23, 2012 for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 7 pages.
- Response to Non-Final Office Action filed on Aug. 23, 2012 for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 7 pages.
- Response to Final Office Action filed on Jan. 9, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 23 pages.
- Response to Final Office Action filed on Mar. 23, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 25 pages.
- Response to Final Office Action filed on Apr. 12, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 11 pages.
- Written Opinion mailed on Aug. 16, 2007 for PCT Application No. PCT/US2006/038163, filed on Sep. 29, 2006, 4 pages.
- ADA Consensus Development Panel. (Jan.-Feb. 1987). "Consensus Statement on Self-Monitoring of Blood Glucose," *Diabetes Care* 10(1):95-99.
- ADA (Jan. 1994). "Self-Monitoring of Blood Glucose," Consensus Statement *Diabetes Care* 17(1):81-86.
- Anonymous. (Sep. 30, 1993). "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus." *The New England Journal of Medicine* 329(14):977-986.
- Anonymous. (Jun. 23, 1998). Taking the "Ouch" Out of Needles: Arrays of "Microneedles" Offer New Techniques for Drug Delivery, *Science Daily*, located at <<http://www.sciencedaily.com/releases/1998/06/980623045850.htm>>, last visited Jan. 14, 2014, 3 pages.
- Beregszászi, M. et al. (Jul. 1997). "Nocturnal Hypoglycemia in Children and Adolescents with Insulin-Dependent Diabetes Mellitus: Prevalence and Risk Factors," *J. Pediatrics* 131(1 Pt. 1):27-33.
- Chase, H.P. et al. (Feb. 2001). "Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes," *Pediatrics* 107(2):222-226.
- Clarke, W.L. et al. (Sep.-Oct. 1987). "Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose," *Diabetes Care* 10(5):622-628.
- Collison, M.E. et al. (Sep. 1999). "Analytical Characterization of Electrochemical Biosensor Test Strips for Measurement of Glucose in Low-Volume Interstitial Fluid Samples," *Clinical Chemistry* 45(9):1665-1673.
- Cox, D.J. et al. (Jun. 1997). "Understanding Error Grid Analysis," *Diabetes Care* 20(6):911-912.
- D'Arrigo, T.D. (Mar. 2000). "GlucoWatch Monitor Poised for Approval," *Diabetes Forecast*, 53(3):43-44.
- Feldman, B. et al. (2000). "FreeStyle[®] M: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing," *Diabetes Technology and Therapeutics*, 2(2):221-229.
- Johnson, R.N. et al. (Jan. 1998). "Accuracy of Devices Used for Self-Monitoring of Blood Glucose," *Annals of Clinical Biochemistry* 35(1):68-74.
- Johnson, R.N. et al. (Jan. 1999). "Analytical Error of Home Glucose Monitors: A Comparison of 18 Systems," *Annals of Clinical Biochemistry* 36(1):72-79.
- Johnson, R.N. et al. (2001). "Error Detection and Measurement in Glucose Monitors," *Clinica Chimica Acta* 307:61-67.
- Kumetrix, Inc. (Dec. 1999). "Painless Blood Glucose Monitoring, Courtesy of the Mosquito," *Start-Up* pp. 27-28.
- Lee, S.-C. (Jun. 1999). "Light Scattering by Closely Spaced Parallel Cylinders Embedded in a Finite Dielectric Slab," *Journal of the Optical Society of America A* 16(6):1350-1361.
- Mahler, R.J. et al. (1999). "Clinical Review 102, Type 2 Diabetes Mellitus: Update on Diagnosis Pathophysiology, and Treatment," *The Journal of Clinical Endocrinology and Metabolism* 84(4):1165-1171.
- McGarraugh, G. et al. (2001). "Physiological Influences on Off-Finger Glucose Testing," *Diabetes Technology & Therapeutics* 3(3):367-376.
- McNichols, R.J. et al. (Jan. 2000). "Optical Glucose Sensing in Biological Fluids: An Overview," *Journal of Biomedical Optics*, 5(1):5-16.
- Medline Plus. (Jun. 17, 2008)., Medical Encyclopedia, Monitor Blood Glucose-Series: Part 1-4, 6 pages.

(56)

References Cited

OTHER PUBLICATIONS

- Neeley, W.E. et al. (1981). "An Instrument for Digital Matrix Photometry," *Clinical Chemistry* 27(10):1665-1668.
- Neeley, W.E. (1983). "Reflectance Digital Matrix Photometry," *Clinical Chemistry* 29(6):1038-1041.
- Neeley, W.E. (1983). "Multilayer Film Analysis for Glucose in 1- μ L Samples of Plasma," *Clinical Chemistry* 29(12):2103-2105.
- Neeley, W.E. (1988). "A Reflectance Photometer with a Square Photodiode Array Detector for Use on Multilayer Dry-Film Slides," *Clinical Chemistry* 34(11):2367-2370.
- Otto, E. et al. (2000). "An Intelligent Diabetes Software Prototype: Predicting Blood Glucose Levels and Recommending Regimen Changes," *Diabetes Technology and Therapeutics* 2(4):569-576.
- Pfohl, M. et al. (2000). "Spot Glucose Measurement in Epidermal Interstitial Fluid—An Alternative to Capillary Blood Glucose Estimation," *Experimental and Clinical Endocrinology & Diabetes* 108(1):1-4.
- Princen, H.M. (May 1969). "Capillary Phenomena in Assemblies of Parallel Cylinders, I. Capillary Rise Between Two Cylinders," *Journal of Colloid and Interface Science* 30(1):69-75.
- Princen, H.M. (Jul. 1969). "Capillary Phenomena in Assemblies of Parallel Cylinders, II. Capillary Rise in Systems with More Than Two Cylinders," *Journal of Colloid and Interface Science* 30(3):359-371.
- Rebrin, K. et al. (Sep. 1999). "Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring," *American Journal of Physiology* 277(3):E561-E571.
- Smart, W.H. et al. (2000). "The Use of Silicon Microfabrication Technology in Painless Glucose Monitoring," *Diabetes Technology & Therapeutics* 2(4):549-559.
- Svedman, C. et al. (Apr. 1999). "Skin Mini-Erosion Technique for Monitoring Metabolites in Interstitial Fluid: Its Feasibility Demonstrated by OGTT Results in Diabetic and Non-Diabetic Subjects," *Scand. J. Clin. Lab. Invest.* 59(2):115-123.
- Trinder, P. (1969). "Determination of Glucose in Blood Using Glucose Oxidase with an Alternate Oxygen Acceptor," *Annals of Clinical Biochemistry* 6:24-28.
- Yum, S. I. et al. (Nov. 1, 1999). "Capillary Blood Sampling for Self-Monitoring of Blood Glucose," *Diabetes Technology & Therapeutics*, 1(1):29-37.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11

BODY FLUID SAMPLING ARRANGEMENTS**CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application is a Continuation of and claims priority to U.S. patent application Ser. No. 13/752,261, filed Jan. 28, 2013, which is a Continuation of and claims priority to U.S. patent application Ser. No. 13/197,592, filed Aug. 3, 2011, which issued as U.S. Pat. No. 8,360,993 on Jan. 29, 2013, which is a Continuation of, and claims priority pursuant to 35 U.S.C. §120, to, U.S. patent application Ser. No. 11/941,403, filed Nov. 16, 2007, which issued as U.S. Pat. No. 8,012,104 on Sep. 6, 2011, which is a Divisional of, and claims priority under 35 U.S.C. §120 to, U.S. patent application Ser. No. 11/529,613, filed Sep. 29, 2006, which issued as U.S. Pat. No. 8,012,103 on Sep. 6, 2011, which claims priority pursuant to 35 U.S.C. §119 to U.S. Patent Application No. 60/721,966 filed Sep. 30, 2005. The entire contents of each of these applications are hereby incorporated by reference in this application.

FIELD

The present invention relates to devices, arrangements and methods involving body fluid sampling with the assistance of a catalyst. In certain embodiments, the present invention is directed to integrated monitoring and body fluid sampling and monitoring devices and methods that permit both digital and alternative-site body fluid sampling and analysis.

BACKGROUND

In the discussion that follows, reference is made to certain structures and/or methods. However, the following references should not be construed as an admission that these structures and/or methods constitute prior art. Applicants expressly reserve the right to demonstrate that such structures and/or methods do not qualify as prior art.

According to the American Diabetes Association, diabetes is the fifth-deadliest disease in the United States and kills more than 213,000 people a year, the total economic cost of diabetes in 2002 was estimated at over \$132 billion dollars. One out of every 10 health care dollars is spent on diabetes and its complications. The risk of developing type I juvenile diabetes is higher than virtually all other chronic childhood diseases. Since 1987 the death rate due to diabetes has increased by 45 percent, while the death rates due to heart disease, stroke, and cancer have declined.

A critical component in managing diabetes is frequent blood glucose monitoring. Currently, a number of systems exist for self-monitoring by the patient. Most fluid analysis systems, such as systems for analyzing a sample of blood for glucose content, comprise multiple separate components such as separate lancing, transport, and quantification portions. These systems are bulky, and often confusing and complicated for the user. The systems require significant user intervention.

Technology development in the field of self-monitoring of blood glucose has placed the burden of acquiring sufficient blood for conducting a test on the user of the technology. Historically, diabetics have been taught to lance their finger tips to produce blood for conducting the test. Ironically, the fingers are not only one of the most sensitive body parts to pain, but they also are among the areas of skin that are most highly perfused with blood. Earlier versions of consumer-oriented self-monitoring products usually required many

microliters of blood, and the finger tips provided a reasonably convenient area to lance that would be most likely to produce the required volume of blood.

More recently, some self-monitoring systems offer the option to the user to test at alternate sites such as the palm, forearm, or thigh. While these sites are generally known to be significantly less sensitive to the pain associated with lancing, the adoption of alternate site testing has been limited for at least four reasons: (1) only a few meter products have been approved by the FDA for testing at alternate sites at this time; (2) many testers do not know that they can use their device at the alternate sites; (3) many testers find it relatively difficult to express sufficient blood at the alternate sites to perform a test; (4) data published in medical literature on some of the meters shows that there may be a distinct difference between glucose levels measured at alternate sites relative to the finger, particularly when glucose levels are falling and/or the subject may be hypoglycemic. Consequently, there is a perception by the medical community that there may be an increased risk for delayed or improper treatment by the diabetic if they act only on the basis of glucose levels measured from alternate sites. Thus, the finger lancing site remains the most frequently used test site by far.

Lancing devices and the lancets themselves have also evolved somewhat over the past few decades. Some lancing mechanisms may produce relatively less pain by either (1) projecting the lancet in and out of the skin in a more straight path and thus reducing stimulation of percutaneous nerves which provide the pain stimulus; and (2) offering depth control in the lancing device so that the user may balance the expression of sufficient blood against the level of pain. Furthermore, lancet manufacturers offer a variety of lancet sizes, lengths, and tip bevel patterns with some companies claiming that their lancet is less painful than others.

What remains clear is that the most testers, when lancing at the finger, often must put down the lancing device and apply pressure near the finger tip in order to produce sufficient blood for the test strip in the meter. Many instructions for use with conventional meter systems specifically prescribe that the user perform this "milking" process because without it, many will not spontaneously produce the required volume. Applicants have observed this phenomenon in the use of commonly available commercial sampling and meter systems. In a recent study, when a trained professional lanced the finger tips of 16 volunteer diabetic subjects at the maximum depth setting on commercially available device under controlled conditions, only 15% of lanced sites spontaneously produced sufficient blood for the meter to accurately measure glucose levels.

Attempts have been made in the past to take steps toward automation of the testing process at alternate sites. Specifically, the Sof-Tact® System offered by Medisense in the early 2000s had the capability to test automatically at alternate sites without any user intervention, but only after each lancet and test strip had been manually loaded into the device. This meter is no longer available on the market.

A device similar to the Soft-Tact® device is disclosed in U.S. Patent Application Publication No. 2004/0138588 A1. This device attempts to integrate all the functions required to complete a glucose test into one device. This device however still requires the user to load a lancet and a test strip prior to each individual testing event, and fails to describe a catalyst (i.e.—mechanism to stimulate or enhance expression of blood from the lanced wound site) that ensures that a sufficient sample is expressed from the wound.

The device is described in U.S. Patent Application Publication No. 2005/0010134 A1, and U.S. Pat. No. 6,793,633 B2

uses a spring, or motor driven mechanism, to apply pressure around the target wound area. From the description it appears that the user must insert a new lancet and test strip assembly for each test.

Another disadvantage with conventional arrangements such as the ones referenced above is that they involve complex and sometimes ineffective mechanisms for transferring blood or body fluid from the wound to a remote location for analysis. For example, many conventional arrangements and techniques utilize a solid lancet for creating a wound in the surface of the skin. After piercing the skin the lancet is retracted and a separate member, such as a tube, is positioned to transfer the blood or body fluid. Alternatively, an absorbent test strip is moved into position, manually or in an automated fashion, so that it absorbs the sample of blood or body fluid from the wound site. These arrangements and techniques are overly complex, and clearly rely upon the precise positioning of the tube or test strip to transfer the sample of blood or body fluid. When seeking to automate the sampling process, this precise positioning requires rather complex mechanical arrangements and controls that must operate under close tolerances. Such complex systems and arrangements are either costly, unreliable, or both.

Thus, conventional sampling devices and methods are overly reliant upon user intervention, such as milking, in order to consistently express a sufficient quantity of blood from the wound site, or are overly complex and/or lack reliability.

Moreover, while many diabetics continue to test their blood glucose levels with blood from the finger, testing at the alternate sites offers the advantage of significantly less pain when lancing the palm, forearm, etc. Thus, it would be advantageous to have an automatic and fully integrated meter constructed for sampling and/or testing at either the finger and the alternate sites.

SUMMARY OF THE INVENTION

According to the present invention, there are provided body fluid sampling and monitoring devices and methods that may address one or more of the shortcomings noted above associated with conventional systems and devices. According to the present invention, there may also be provided improved body fluid sampling and monitoring devices and methods that enable both digital and alternative-site body fluid sampling without significant user intervention.

As used herein "digital" means fingers or toes. "Digital body fluid" means expression of body fluid from a wound created on the fingers or toes, and encompasses lancing sites on the dorsal or palm side of the distal finger tips.

As used herein "alternate site" means a location on the body other than the digits, for example, the palm, forearm or thigh. "Alternate-site body fluid sampling" means expression of body fluid from the lancing site on a surface of the body other than the fingers or toes, and encompasses lancing sites on the palm, forearm, and thigh.

As used herein, "body fluid" encompasses whole blood, intestinal fluid, and mixtures thereof.

As used herein "integrated device" or "integrated meter" means a device or meter that includes all components necessary to perform sampling of body fluid, transport of body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid.

As used herein, the term "obstructed opening" means that the needle or skin piercing element is not retracted prior to extracting the body fluid from the wound created thereby. Thus, for example, the portion of the opening or wound on or

just below the surface of the skin is at least partially obstructed by the skin piercing member or needle which will be located at the wound opening entrance on or just below the surface of the skin upon extraction of body fluid. This aspect of the present invention is believed to run counter to the conventional wisdom in the art. See, for example, U.S. Pat. No. 6,063,039.

According to one aspect, the present invention is directed to an arrangement for producing a sample of body fluid from a wound opening created in a skin surface at a sampling site, the arrangement comprising: at least one skin-penetration member having a first end configured to pierce the surface of the skin, and an inner lumen in communication with the first end; at least one actuator operatively associated with the at least one skin-penetration member; and at least one catalyst device configured to enhance perfusion of body fluid at the sampling site;

wherein the at least one actuator is configured to locate the at least one skin-penetration member so as to obstruct the wound opening while transporting body fluid through the inner lumen.

According to another aspect, the present invention is directed to a method of sampling body fluid from a wound opening created in a skin surface at a sampling site, the method comprising: automatically or manually initiating a testing sequence; applying a catalyst to the sampling site; actuating a skin-piercing member so as to drive the member into the surface of the skin thereby creating the wound opening; allowing the at least one skin-penetration member to obstruct the wound opening; and transporting body fluid through an inner lumen of the skin-penetration member; wherein the catalyst is applied to the sampling site at one or more of the following times: prior to actuating the skin-piercing member, during actuation of the skin-piercing member, or after actuating the skin-penetration member.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

The following description of preferred embodiments can be read in connection with the accompanying drawings in which like numerals designate like elements and in which:

FIG. 1 is a partial perspective view of an arrangement constructed according to the present invention.

FIG. 2 is a partial cut away side view of the arrangement of FIG. 1.

FIG. 3 is a partial cut away side view of the arrangement of FIG. 1, with an activated catalyst.

FIG. 4 is a partial cut away magnified side view of the arrangement of FIG. 1, with an activated catalyst and illustrating a mechanism of body fluid collection and transport according to the present invention.

FIG. 5 is a perspective view of a portion of an arrangement, including an actuator, constructed according to the present invention.

FIG. 6 is a perspective view of an integrated device formed according to one embodiment of the present invention.

FIG. 7 is a partial side view of the integrated device of FIG. 6.

FIG. 8 is a perspective view of a component of the integrated device of FIG. 6.

FIG. 9 is a partial perspective view of various components of the integrated device of FIG. 6.

FIG. 10 is a side view illustrating various additional components of the device of FIG. 6.

FIG. 11 is a perspective view of an integrated device formed according to an alternative embodiment of the present invention.

DETAILED DESCRIPTION

According to a first aspect of the present invention, there are provided arrangements and techniques for reliably expressing body fluid from a digit or from an alternate site. For example, according to the present invention, arrangements and techniques are provided which consistently and reliably express an amount of body fluid that is sufficient to perform an analysis to quantify the amount of an analyte (e.g., glucose, bilirubin, alcohol, controlled substances, toxins, hormones, proteins, etc.) contained therein.

One embodiment of an arrangement 10 of the type described above is illustrated in FIGS. 1-4. As illustrated therein, the arrangement 10 may include a housing 12. The housing 12 may have any suitable shape or configuration, and is not limited to the shape and configuration illustrated. The housing 12 can be constructed of any suitable material. For example, the housing 12 may be constructed of a polymeric or metallic material.

The arrangement 10 may further include a catalyst to assist in the sample acquisition process by enhancing perfusion of blood or body fluid at a sampling site. At least one of several catalysts may be utilized or included in the arrangement of the present invention. Possible catalysts include, lancing velocity, heat, pressure, vacuum, vibration, and topical drugs (which induce vasodilatation and increases the blood or body fluid available at the lancing site). These catalysts may be applied before, during, after lancing, or in combination with some or all three to facilitate expression of sufficient quantity of body fluid for determination of the concentration of an analyte contained therein (e.g., glucose).

Lancing velocity refers to the speed at which the skin piercing member is driven. Velocities ranging from ~0-22 m/s are possible. Both pain and blood production may increase as velocity increases. Attempts to balance pain and blood have led to a preferred range of about 3-20 m/s, 3-10 m/s, or 10-12 m/s.

Pressure is another possible catalyst. Footprint contact pressure can be varied by a number of possible techniques. One such technique is to vary the size of the opening of the footprint. Another form of pressure catalyst can take the form of a pressure-applying member that circumferentially surrounds and squeezes the digit or other body part from which a sample is to be acquired. One illustrative example of this form of catalyst is a pressure-applying cuff-like member of the type described in U.S. patent application Ser. No. 11/510,784, entitled BODY FLUID MONITORING AND SAMPLING DEVICES AND METHODS, the entire content of which is incorporated herein by reference. The above-described pressure catalyst can be utilized alone, or in combination with other catalysts such as vacuum pressure.

Heat is another optional catalyst. Increasing heat, thereby increasing the skin temperature at the wound site, increases blood production. Possible implementations of heat include IR lights, or resistive elements to heat the skin.

Another catalyst is vacuum pressure. According to certain embodiments, a light vacuum (e.g., 3-8 in. Hg) is applied to the wound site before, during, and/or after lancing. Several embodiments for applying vacuum to the wound site are contemplated. One embodiment uses a motor driven pump to apply vacuum. Alternative embodiments include using individually packaged vacuum chambers to apply vacuum, or

using a rigid syringe like mechanism to apply vacuum. Other systems use motor driven pumps and syringes.

According to the principles of the present invention, one or more of the above-described catalysts can be used in combination with each other, either concurrently or sequentially.

In certain specific embodiments of the arrangement 10, a catalyst device 14 can be included which comprises a member or combination of members for applying pressure to a surface of the skin S disposed at a location which is proximate to an area from which a sample of body fluid is to be expressed (i.e., sampling site 28). The catalyst device 14 may cause the area of the skin from which the sample of body fluid is to be expressed to become perfused with blood and/or body fluid. This effect facilitates expression of body fluid from a wound opening 30. According to the illustrated embodiment, the catalyst device 14 comprises a member or combination of members, such as the illustrated pump 16 and related controller 18.

The arrangement 10 further comprises a footprint 20 which is attached to the housing 12. According to the illustrated embodiment, a digit D is placed on the footprint 20 at the sampling site. However, it should be understood that the footprint may also be applied to the surface of the skin at an alternate site. The footprint 20 has a central opening and may optionally have an annular in shape. However, the footprint is not limited to this shape or configuration. Numerous shapes or configurations may satisfy the function of providing a footprint around the site from which body fluid is to be expressed. The footprint can have an opening of any suitable diameter or major dimension 21. According to an illustrative example, the diameter or major dimension is at least about 3-8 mm. According to certain embodiments, the footprint 20 is constructed from a material which facilitates the formation of a seal between the digit D and the footprint 20. For example, suitable materials for this purpose include a relatively soft elastomeric material, such as a silicone rubber.

The arrangement 10 further includes at least one skin penetration member 22. The at least one skin penetration member 22 can take any suitable form. For example, the at least one skin penetration member can comprise a solid lancet or a hollow needle. Conventional arrangements often require separate mechanisms for drawing a sample of blood to the surface of the skin and for transporting the sample to a reaction chamber. The device of the present invention can use a skin-piercing element in the form of a hollow needle to both create and transport the sample, thereby greatly simplifying and improving the effectiveness of the arrangement 10. According to one optional embodiment, the skin-penetration member(s) 22 can be in the form of a so-called "microneedle." As the name implies, microneedles are characterizable by their relatively small outer diameters. For example, a microneedle, as the term is utilized herein, may encompass a skin-penetration member having an outside diameter which is on the order of 40-200 μm . The inside diameter can vary, for example, having an inside diameter on the order of 25-160 μm . Needles are also characterizable in the art by reference to the "gauge." By way of illustration, and consistent with the above description, microneedles having a gauge ranging from 26-36 are clearly comprehended by the present invention. Certain advantages may be gleaned from the use of such microneedles as the skin-penetration member. In particular, due to their small size, the size of the wound left upon entry into the skin is relatively small, thereby minimizing the pain associated with such needle insertions and allowing for a quicker healing process. However, the present invention is certainly not limited to the use of such microneedles. Thus, for example, according to one possible alternative embodi-

ment, the skin penetration member(s) comprise hollow needles having a gage of about 20-25, or comprising hollow needles having an inner diameter of about 0.007 inches and an outer diameter of about 0.020 inches.

The at least one skin-penetration member **22** can be formed of any suitable material, such as metal, plastic, glass, etc. Optionally, the at least one skin penetration member can be mounted to a hub **24**. In further alternative embodiments, the hub **24** may contain an assay pad **34** comprising a reagent that changes color upon reaction with a target analyte, as known per se to those skilled in the art. As illustrated, for example, in FIG. 2, the skin-penetration member **22** and hub **24** may be located within a chamber **25**. The chamber **25** is in communication with pump **16** so that vacuum pressure can be applied within the chamber **25**. The arrangement **10** can comprise a plurality of skin penetration members **22**. According to certain embodiments, the plurality of skin penetration members **22** can be provided in the form of a replaceable cartridge. The at least one skin penetration member **22**, and/or the hub **24** are attached to an actuation element **26**. The actuation element **26** can take any suitable form. For example, the actuation element **26** may comprise a mechanical, electrical or pneumatic element. According to the Illustrated embodiment, the actuation element **26** is in the form of a mechanical spring, more specifically, in the form of a torsional spring.

According to certain embodiments of the present invention, the catalyst device **14** operates in an automatic or semi-automatic manner. For example, a user may place the footprint **20** over a surface of the skin on a digit D, or at an alternate site. When the user is ready to produce a sample of body fluid, the button B is pressed. This can initiate a programmed sequence of events in the device including actuation of the catalyst device **14**, thereby applying vacuum pressure to the skin an area proximate the tip region of digit D or alternate sampling site (FIG. 3) for a predetermined period of time. The skin-penetration member **22** can then be driven into the skin (FIG. 4). At a predetermined time, the catalyst device **14** is deactivated. This mode of operation can be characterized as "semi-automatic" in that sequence of events must be manually initiated by the user via pressing the button B.

According to one alternative, the mode of operation can be fully automatic. For example, the user places a tip region of digit D on the footprint **20**, or places the footprint over an alternate site. The arrangement **10** can be provided with one or more sensors **27** that detect and verify that the footprint is properly located and ready for the sampling procedure to begin. Once this state has been sensed, the device automatically activates the catalyst **14** which is applied to the skin at the sampling site **28** (FIG. 3) for a predetermined period of time. Subsequently, the at least one skin penetration member **22** is driven into the skin (FIG. 4). At a subsequent predetermined time, the catalyst device **14** is deactivated. The catalyst device can be deactivated before, during or after the skin-piercing member is driven into the skin.

The arrangement **10** can form at least part of a device which functions only to sample body fluid. For example, the arrangement **10** can be used to express body fluid from the skin in the form of a drop of blood which pools on the surface of the skin of the user. This drop of blood can then be transferred to another separate device which then transports and/or analyzes the sample for a target analyte. Alternatively, the arrangement **10** may express a sample of body fluid from the skin, and then transport the sample to a location which can then be accessed for further analysis by a separate device. For instance, the sample body fluid can be transported to a reagent-containing pad **34**, also contained within the arrangement **10**. The sample then reacts with the reagent to produce

a detectable spot or signal. The reagent pad can then be analyzed by a separate meter using photochemical, electrochemical, or other suitable techniques known per se to those skilled in the art. The reagent pad can remain within the arrangement **10** during the aforementioned analysis. According to an alternative embodiment, the reagent pad **34** can be analyzed by a detector **36** that forms part of the arrangement **10**. Alternatively, the reagent pad can be removed from the arrangement **10** and inserted into a separate device, such as an electrochemical or photometric meter.

As illustrated, for example, in FIG. 4, according to this optional aspect of the present invention a skin-piercing member **22** in the form of a needle having a first end **22e** configured to pierce the skin and an inner lumen **22f** is driven into the skin to create a wound opening **30** therein for producing a sample of body fluid **32**, preferably blood. The needle is not retracted right away, instead it is allowed to dwell and obstruct the opening **30** created in the surface of the skin. Blood or body fluid **32** is then extracted and flows through the inner lumen **22f** of the needle, and is eventually transported to a site within the arrangement **10** for further analysis. The blood or body fluid **32** is drawn through the inner lumen by any suitable mechanism, such as capillary action, vacuum, or a combination of both. The needle **22** may be caused to dwell at the desired location via any of the mechanisms described herein. The skin-piercing member **22** is eventually retracted (see, e.g., FIG. 2). It has been surprisingly observed that an adequate sample volume can be extracted by the above-described arrangement/technique, especially when utilizing a vacuum catalyst. This arrangement and technique is advantageous in that a skin piercing member **22** may be used for wound creation and sample transport. Complex mechanisms and arrangements for repositioning a transport member or assay pad to a location that does not obstruct the opening can be avoided. Other advantages of obstructed opening sampling is realizing a reduction in the required sample volume, and improving the reliability of obtaining an adequate sample. When the needle is located so as to obstruct the wound opening, the end of the needle is closer to the source of body fluid, thus smaller drops of sample are more likely to reach the inner lumen of the needle and be successfully transported as the needle rests on or in the skin. By contrast, when the needle is withdrawn away from the surface of the skin, as in conventional arrangements and techniques, the droplet of blood or body fluid must be significantly larger/taller to reach the end of the needle and lumen, thereby elevating the risk that an insufficient sample is obtained.

As illustrated in FIG. 5, each individual skin-piercing element **22** is provided with its own actuation element or torsional spring **26**. The torsional spring elements **26** may be provided to the user in a pre-cocked position. The acceleration path of the skin-piercing element or needle **22** may begin up to 180 degrees from the angle of impact with the skin S of the user. According to one beneficial aspect, the pivot point of the torsional spring elements can be provided as close as possible to the plane lying on the surface of the skin S in order to ensure that the skin piercing element **22** strikes the skin at an angle which is as close to 90 degrees as possible. The torsional spring element **26** can act as a guide for the skin-piercing element or needle **22** to that locates the tip **22e** thereof so as to obstruct the wound opening **30** so as to draw the blood **32** into the lumen **22f** of the needle. In this regard, the torsional spring element **26** may be designed such that its neutral position R_0 will locate the needle so as to obstruct the wound opening **30** created by the skin piercing operation.

Another advantage of this optional aspect of the present invention is that the torsional spring elements **26** do not

require a positive stop to limit the penetration depth of the skin-piercing element **22**. It has been observed that elimination of a hard stop may provide certain beneficial effects. Namely, it has been observed that devices that include a hard stop experience a shock and resulting vibration and/or stirring action when the stop is impacted. It is theorized that this motion may increase the observable wound and/or the perceived pain associated with sampling. According to this embodiment, the depth of penetration of the skin-piercing member **22** is determined by a number of factors, including the design of the sharp, the actuation force and the skin's resistance to penetration at the chosen sampling site. The lack of a positive stop has not been observed as increasing pain in clinical studies.

An exemplary body fluid sampling method or technique which may be used in conjunction with any of the above-described arrangements, but is not necessarily limited thereto, is described as follows.

A footprint is placed over a sampling site located on a digit or at an alternate site. The footprint has an opening therein which defines the sampling site. A sequence of events is then initiated. The events can be initiated manually, for example, by pressing a button or other triggering mechanism. Alternatively, the events can be automatically triggered, for example, through the use of sensors which determine when the footprint has been properly positioned over a sampling site on the surface of the skin. A catalyst is then applied to the sampling site. The catalyst can comprise one or more of lancing velocity, heat, pressure, vacuum, vibration, topical drugs, or combinations thereof. These catalysts can be applied concurrently or sequentially relative to one another. According to one embodiment, a catalyst in the form of vacuum pressure is applied to the sampling site via a suitable mechanism, such as a pump capable of creating vacuum pressure. The catalyst can be applied for a set period of time, and then removed or terminated. For example, the catalyst can be removed before, during, or after penetration of the skin. Next, at least one skin penetration member is actuated or driven into the surface of the skin. The skin penetration member can take any suitable form, such as a solid lancet or hollow needle (e.g., a microneedle). According to one embodiment, at least one skin penetration member comprises a hollow needle having a first end configured to pierce the surface of the skin, and an inner lumen. The at least one skin penetration member can be actuated via any suitable mechanism, such as a mechanical spring. According to one optional embodiment, the actuating mechanism comprises a torsional spring. The at least skin penetration member is caused to dwell at or below the surface of the skin in the vicinity of the wound opening in order to obstruct the same. The skin penetration member can be caused to dwell at this location via any suitable mechanism. According to one embodiment, the actuator is provided in the form of a torsional spring having a resting position which can be utilized to cause the first end of the at least one skin penetration member to obstruct the wound opening subsequent to piercing the surface of the skin. During the period of time in which the at least one skin penetration member is caused to dwell at the wound opening, body fluid is transported away from the wound site via a suitable mechanism. According to one embodiment, the body fluid, or blood, is transported via the inner lumen of a hollow skin-penetration member via capillary action, vacuum, or a combination of both. According to one optional embodiment of the present invention, a mechanism can be provided which estimates the acquired sample volume, and compares this measured sample volume with a target sample volume. The information acquired by this analysis can be used to control the catalyst

such that it is automatically removed once the target sample volume has been acquired. Any suitable mechanism can be utilized to analyze the acquired sample volume. For example, the body fluid can be transported to an assay pad which contains a chemical reagent impregnated therein. Upon exposure to the body fluid, a target analyte contained therein causes a chemical reaction producing a color change in the assay pad. This color change can in turn be detected by a suitable detection element. One such detection element utilizes colorimetric optical analysis of the assay pad. More specifically, an array of such detection elements can be provided along a longitudinal length of the assay pad. The number of detection elements contained along the length of the assay pad that detect the presence of the sample can be correlated to the acquired sample volume. For example, the further the sample volume travels along the length of the assay pad the greater the acquired sample volume. Once it has been determined that a target sample volume has been acquired, the catalyst can then be terminated. This can be accomplished by the use of a controller in signal communication with a pump. The controller operates based on signals derived from the analysis of the sample volume in the manner described above. Some advantages of monitoring volume to actively control the application of the catalyst include reduction in expression of excess blood or body fluid thereby reducing mess, preventing damage to skin (bruising, etc) due to prolonged catalyst application, and reduction in power consumption.

According to a further optional aspect of the present invention, the above-described arrangements and methods can form at least part of an integrated device or integrated meter. As previously noted, as used herein, the term "integrated device" or "integrated meter" means a device or meter that includes all components necessary to perform sampling of the body fluid, transport of the body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid. Thus, according to the principles of the present invention, an integrated device or meter can comprise one or more, or any combination, of the features previously described herein. According to further aspects of the present invention, and integrated meter or device can comprise components and/or features in addition to those specifically described herein.

An exemplary integrated meter is illustrated in detail in FIGS. 6-10. As illustrated therein, the integrated meter **100** generally comprises a housing **112** and a catalyst device **114** (e.g., FIG. 10). The catalyst device **114** may take any suitable form and can comprise any of the previously described alternative catalyst devices. The integrated meter **100** may further comprise a footprint **120** of the type previously described. A door **123** can be provided on the housing **112**. The door **123** is connected via a hinge **125** to the housing **112**. As described in further detail below, the door **123** can be opened to reveal a cartridge **131** containing a plurality of skin-piercing elements **122**. In the illustrated embodiment, the integrated meter **100** further includes a display **127** for communicating the results of the analysis on the sample body fluid for the presence and/or concentration of an analyte contained therein. The integrated meter **100** may further include one or more buttons **129** which can be pressed by the user to engage various functions and interfaces of the integrated meter **100**.

FIG. 7 is an illustration of the integrated meter **100** with the door **123** opened to reveal further details of the interior components of the exemplary integrated meter **100**. As illustrated therein, the housing **112** contains a cartridge **131** therein. In the illustrated embodiment, the cartridge **131** is circular and contains a plurality of skin-piercing elements as further

11

described herein. The cartridge **131** is mounted about a hub **133** and is rotatable. Thus, upon sampling a skin-piercing element **22** is driven through an opening in the housing in registry with the footprint **120** and pierces the skin of the user. Once the test has been completed, the cartridge **131** can be rotated such that an unused skin-piercing element now comes into registry with the opening in the housing and the corresponding opening in the footprint **120** in preparation for the next sampling event. It should be understood that the present invention is not limited to the illustrated circular cartridge having the particular configuration depicted in the drawing figures. To the contrary, a number of alternative cartridge configurations are possible, such as a slidable linear or polygonal configuration (not shown). Also illustrated in FIG. 7 is the presence of a light source **139** disposed on the back of the door **123**. The light source **139** can take any suitable form, such as a light emitting diode. It should be understood that alternative light sources may also be utilized. The function of the light source **139** will be described in further detail below.

Further details of the optical assembly **135**, the light source **139**, and the replaceable cartridge **131** are illustrated in FIGS. 8-9. As illustrated therein, the replaceable cartridge **131** generally may comprise a plurality of compartments defining a plurality of body fluid sampling and analysis sites **132**. Contained in each sampling and analysis site **132** is a skin penetration member **122**. Each skin penetration member **122** can take any suitable form. According to the illustrated embodiment, each skin penetration member **122** is in the form of a hollow needle. It should be understood that alternative skin penetration members may also be utilized consistent with the principles of the present invention (e.g., solid lancets, etc.) each skin-penetration member can be attached to a needle hub **124**. Each needle hub **124** is, in turn, attached to an actuation element **126**. It should be understood that a number of different actuation elements may be utilized according to the principles of the present invention. The actuation elements can be mechanical, electrical, pneumatic, etc. According to the illustrated embodiment, the actuation element **126** is in the form of a torsional spring and may have those features and characteristics previously described herein. Upon activation, the torsional spring drives the needle hub **124** and the attached skin penetration member **122** into the skin of the user disposed on the footprint **120**. According to certain embodiments, each sampling/analysis site **132** further contains a signaling mechanism which produces a detectable signal when contacted with a target analyte contained in a sample of body fluid expressed from the skin. A number of suitable mechanisms are envisioned. The mechanisms may be based on technologies such as photometric or electrochemical analysis. According to the illustrated embodiment, each needle hub **124** contains a reagent pad **129** which generally comprises an absorbent material containing a chemical reagent which, upon reaction with a target analyte, produces a chemical reaction that results in a detectable signal. The reagent pad **129** is in fluid communication with the inner lumen of the skin piercing element **122**. As noted above, the signal can be detected optically, electrochemically, or by other suitable means. According to one embodiment, the reagent pad **129**, upon reaction with the target analyte, produces a spot which is optically detected by the optical assembly **135** in a manner generally known to those skilled in the art. The spot produced by the above-mentioned reaction can be observed optically through a window **143** formed along the interior region of the illustrated cartridge **131** by the optical assembly **135**. In this regard, light emitted from the light source **139** is incident upon the reagent pad **129**, and reflects off the surface thereof. Upon formation of a reaction spot on

12

the surface of the reagent pad **129**, the amount of light reflected off the reaction spot differs from the light reflected off of other portions of the reagent pad **129** containing no such reaction spot. This reflected light is picked up by the optical assembly, first through the lens **137** (FIG. 7), and eventually is incident upon an optical detector element **142** (FIG. 9).

The optical detector element **142** generally comprises one or more detector elements. According to one alternative construction, the detector element **142** comprises a plurality of detector elements formed in an array. The array can take any suitable configuration, and can be a linear array or an area array according to one nonlimiting example. The detector elements can comprise any suitable construction. For example, the detector elements **142** can comprise a photo diode, CCD, or CMOS based detector element. The signals transmitted to the detector element **142** are passed on to suitable electronics contained within the housing **112** (see, e.g., FIG. 10) via suitable electrical connectors, such as flexible ribbons **141**. The specifics of the electronics and signal interpretation being familiar to those of ordinary skill in the art. While not necessary to enable practice of the presently claimed invention, further details concerning the structure, function, and arrangement of the optical assembly **135**, and the components contained therein, can be gleaned from the disclosure contained in U.S. Patent Application Publication No. 2006/0281187, entitled ANALYTE DETECTION DEVICES AND METHODS WITH HEMATOCRIT/VOLUME CORRECTION AND FEEDBACK CONTROL, the entire content of which is incorporated herein by reference.

Additional components of an integrated meter **100** are illustrated in FIG. 10. The view depicted in FIG. 10 is that of an integrated meter **100** with the back panel removed to reveal the above-referenced additional components. For example, as illustrated in FIG. 10, the integrated meter **100** may further include a plurality of rollers **147** which cooperate with the cartridge **131** and a motor drive **149** thereby enabling the rotation of the cartridge **131** about the hub **133**, and indexing of the analysis sites **132** with the footprint **120**. The integrated meter **100** may also include a catalyst device **114** comprising a pressure pump **151** which, according to certain embodiments, comprises a pump capable of producing at least a negative or vacuum pressure at the surface of the skin located over the footprint **120**. The integrated meter **100** may further include appropriate electronics, as embodied in the circuit board **153** of the illustrated embodiment. Preferably, the circuit board contains conventional electronic components capable of controlling the various functions of the integrated meter **100** in the desired manner, including the pump **151**. The particulars of the circuit board **153** and electronic components disposed thereon, being well-known to those of ordinary skill in the art. The integrated meter **100** may further comprise a suitable power supply **155**, such as the illustrated batteries.

As evident from FIGS. 6-10, the integrated meter **100** is configured for handheld use. However, the invention is not limited to handheld devices. For example, the present invention is also directed to integrated meters that are wearable. An example of such a wearable device is illustrated in FIG. 11. The wearable integrated device **200** illustrated therein can be generally composed of a functional portion **202** and a body-attachment portion **204**. The functional portion can comprise an arrangement **10** of the type described herein. The functional portion can also have one or more of the features and elements of the handheld integrated meter described above.

According to further aspects of the present invention, modified devices and techniques are provided which permit both digital body fluid sampling and analysis as well as alter-

13

nate-site body fluid sampling and analysis, which may be performed at the election of the user. In the description that follows, it should be understood that the integrated meters described herein may have any of the features and/or modes of operation than that of the previously described embodiments. For example, the integrated meter that incorporate arrangements of the present invention can include features that facilitate use on digits as well as alternate sites, at the election of the user. Such features are described in U.S. patent application Ser. No. 11/510,784, entitled BODY FLUID MONITORING AND SAMPLING DEVICES AND METHODS, the entire content of which is incorporated herein by reference.

An exemplary body fluid sampling and analysis methodology or technique, which may be utilized in conjunction with any of the above-mentioned catalyst devices or integrated meters, but is not necessarily limited thereto, is described as follows.

A user loads a fresh disposable cartridge containing a plurality of skin penetration members and analysis sites into an integrated meter. The integrated meter then reads calibration data contained in or on the cartridge. This data can be read in any suitable manner. For example, a bar code may be placed on the cartridge which can be optically read by the optical assembly contained within the meter. The integrated meter then selects the proper lookup table or algorithm to calculate an aggregate glucose measurement taking into consideration the calibration data. The meter may then place itself in a ready mode waiting for a trigger to initiate sampling and testing. The user then either manually presses a button or trigger to initiate sampling and analysis, or the device verifies that it is properly positioned on the skin of the user and ready to begin the sampling and analysis procedure. Suitable sensors to accomplish this include optical, capacitive or pressure sensors. The device then initiates a catalyst which acts to facilitate the expression of body fluid. Alternatively, the catalyst is vacuum pressure which generates suction at the sampling site. Optional sensors present in the meter may be used to monitor and control the positive or negative pressure of the catalyst. After achieving a target pressure for a desired period of time, the skin penetration member (e.g., a hollow needle) is actuated and driven into the skin of the user to create a wound site. The skin penetration member comes to rest in or directly on the wound opening created at the sampling site where it obstructs the wound opening and is in the desired position for collecting a sample of body fluid expressed from the wound. The integrated meter may further include a mechanism for detecting a whether a sufficient amount of sample has been expressed. Details of such suitable detection techniques are described in detail in U.S. Pat. No. 7,052,652, entitled ANALYTE CONCENTRATION DETECTION DEVICES AND METHODS, the entire content of which is incorporated herein by reference. Once the desired amount of body fluid has been obtained, the catalyst is deactivated. A sample of body fluid is in fluid communication with a device or mechanism which creates a detectable signal upon reaction within analyte present in the sample body fluid. For example, one such suitable mechanism is an absorbent pad containing a chemical reagent which, upon reaction with the analyte produces a reaction spot which can be optically detected. An optical assembly which is in optical communication with the above described signal generating mechanism is utilized to detect the signal created via reaction with the analyte and communicate the signals to supporting electronics contained within the meter. The concentration of a target analyte (e.g., glucose) can then be calculated using these signals as a basis. Additional factors may be considered during these calculations,

14

such as the sample size, levels of other substances contained in the sample (e.g. hematocrit), etc. Such optional calculation techniques are described in further detail in U.S. Patent Application Publication No. 2006/0281187, entitled ANALYTE DETECTION DEVICES AND METHODS WITH HEMATOCRIT/VOLUME CORRECTION AND FEEDBACK CONTROL, the entire content of which is incorporated herein by reference. These calculations quantify the amount of analyte contained in the sample body fluid. This quantity is displayed on a suitable display contained within the meter which can be easily read by the user. The integrated meter then automatically may retract the skin-penetration member and indexes the disposable cartridge to present a fresh unused skin penetration member which will be utilized to perform the next sampling and analysis event.

Example

A prototype was constructed using a torsional spring actuator and a needle designed to position the needle on or in the wound (i.e., to obstruct the wound opening). A vacuum catalyst was also utilized. Results of an evaluation of this prototype are summarized in the following table.

Population	Camino Medical	Camino Medical
Experiment Name	PAMF1	PAMF2
Actuator	Beam	Torsional
Actuator Version	2.1	5.0 (w/dwell)
# of Subjects	21	19
Probability BV > 250 nl	94%	93%
Probability BV > 300 nl	90%	91%
Probability BV > 350 nl	85%	85%
Average BV (nl)	985	1137

The table shows two experiments for which the lancet design, footprint design and footprint contact force were identical. Experiment PAMF1 used a cantilevered beam actuator; this actuator did not allow the needle to remain in or on the wound. Experiment PAMF2 used a torsional coil actuator, this actuator caused the needle to dwell the needle in or on the skin. Surprisingly, the performance of the torsional coil was comparable in blood volume (BV) probabilities to the cantilevered beam. Even more surprising was the observation that the torsional coil actually produced a slightly higher average blood volume.

Numbers expressing quantities of ingredients, constituents, reaction conditions, and so forth used in this specification are to be understood as being modified in all instances by the term "about". Notwithstanding that the numerical ranges and parameters setting forth, the broad scope of the subject matter presented herein are approximations, the numerical values set forth are indicated as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective measurement techniques. None of the elements recited in the appended claims should be interpreted as invoking 35 U.S.C. §112, ¶6, unless the term "means" is explicitly used.

Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention as defined in the appended claims.

We claim:

1. An arrangement for producing a sample of body fluid from a wound opening created in a skin surface at a sampling site, the arrangement comprising:

15

a cartridge comprising a plurality of compartments and a plurality of sampling sites, wherein each of the sampling sites comprises

a skin-penetration member having a first end configured to pierce the surface of the skin, and an inner lumen in communication with the first end;

a spring actuator operatively associated with the skin-penetration member; and

a needle hub connecting the skin-penetration member and the spring actuator, wherein the needle hub comprises a reagent pad and wherein the spring actuator is configured to drive the skin-penetration member to form the wound opening; and

a detector assembly,

wherein each of the compartments at least partially encloses the skin-penetration member, spring actuator, and needle hub of a respective sampling site of the plurality of sampling sites.

2. The arrangement of claim 1, wherein the spring actuator drives the skin penetration member in an arcuate path.

3. The arrangement of claim 1, further comprising at least one catalyst device comprising a means for applying vacuum pressure, positive pressure, or heat to the sampling site.

16

4. The arrangement of claim 3, wherein the catalyst device comprises a pump, and wherein the pump is configured and arranged to apply a vacuum to the sampling site.

5. The arrangement of claim 4, further comprising a controller operatively associated with the pump.

6. The arrangement of claim 1, further comprising a housing, and wherein a footprint is disposed on the housing to be applied to the sampling site on the skin of a user.

7. The arrangement of claim 6, wherein the footprint has an opening, and wherein the opening has a diameter or major dimension of 3-8 mm.

8. The arrangement of claim 6, wherein the footprint comprises an elastomeric seal.

9. The arrangement of claim 1, wherein the detector assembly comprises at least one CMOS-based detector element.

10. The arrangement of claim 9, wherein the detector assembly comprises a linear or area array of CMOS-based detector elements.

11. The arrangement of claim 1, wherein the skin-penetration member comprises a microneedle.

* * * * *